AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 bln deal
AstraZeneca said on Tuesday
it had agreed to buy China-based Gracell Biotechnologies to support its cell therapy ambitions, in a deal valued
at approximately $1.2 billion.
it had agreed to buy China-based Gracell Biotechnologies to support its cell therapy ambitions, in a deal valued
at approximately $1.2 billion.
(Reporting by Urvi Dugar in Bengaluru; Editing by Sonia Cheema)
((UrviManoj.Dugar@thomsonreuters.com;))
nL4N3DL0SX